PerkinElmer has entered into a definitive agreement to acquire the assests of Caliper Life Sciences for $600m.
The acquisition allows PerkinElmer to expand its solutions and services for molecular, cellular, animal and tissue imaging to enable translational medicine research.
The transaction will add microfluidics platform for genomics and proteomics applications, sample preparation technologies for scientific workflow areas such as Next Generation DNA sequencing.
The combined technology platforms will expand solutions and services for identification of therapeutic response, biotherapeutics development and biologics QA/QC.
The deal allows platform technology additions for the detection of environmental contaminants and food pathogens and broadens services for multi-vendor asset management, custom research, and profiling for contaminants and adverse effects.
PerkinElmer chairman and CEO Robert Friel said the R&D, application expertise and intellectual property of the combined organization will provide their customers with enhanced knowledge and services,
Caliper Life Sciences CEO Kevin Hrusovsky said he is excited by both PerkinElmer’s ability to leverage its global reach for the delivery of solutions and the opportunity to accelerate the development of important advances that make a difference in improving human and environmental health.